Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Follow Brielle on Twitter @Brielle_Benyon.
An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.
The COVID-19 pandemic drastically impacted many facets of cancer care. Although some changes were detrimental, an expert from Johns Hopkins Medicine notes others actually improved accessibility to care.
When Joseph Heisler was diagnosed with von Hippel-Lindau disease 30 years ago, there was hardly any information on the condition. Fast forward three decades, there is an FDA-approved drug and a handbook of information available in two languages.
The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.
Lorelei Colbert was diagnosed with triple-negative breast cancer at 28 and used her experience to launch the “Chemo to Kindness” challenge that inspired others around the world to do acts of good.
From when to replace masks to addressing a CDC-recommended strategy to improve the effectiveness of surgical masks, Dr. Tatiana M. Prowell of Johns Hopkins Medicine offers masking tips for patients with cancer.
After promising phase 3 clinical trial results, the FDA will consider Libtayo for approval to treat patients with advanced non-small cell lung cancer, regardless of PD-L1 status.
Prostate cancer survivors are encouraged to include their partners in interventions to improve sexual function after treatment — and, as study results show, it is better to have these conversations with providers sooner rather than later.
After the drug showed promising results in the DESTINY-Breast03 trial, the FDA granted Enhertu a priority review, meaning that it plans to make its approval decision on it by the end of the second quarter of 2022.
While robotic navigational bronchoscopy is an exciting advancement in diagnosing and staging lung cancer, the procedure does come with some risks and factors to consider, explained one expert.
An infectious disease expert explains the new and upcoming treatment modalities that are improving COVID-19 outcomes for patients with cancer and other conditions that compromise the immune system.
The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.
From mouth sores to cold sensitivities as well as a continued taste of chemicals, cancer survivors recently shared some of the more unexpected side effects they experienced during and after treatment.
The Food and Drug Administration is expected to decide on whether to approve certain cancer regimens within the first few months of the year. Here’s what patients with cancer should know.
Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.
The recent FDA approval of Keytruda, an immunotherapy monoclonal antibody drug, for children with melanoma is an exciting development, according to an expert. But there is potential for certain side effects that children and their family should consider before undergoing treatment.
From long-term effects of pediatric cancer to a survivor fulfilling her dream of being an astronaut, CURE® looked back on its most-read childhood cancer stories of the year.
The Food and Drug Administration will offer guidance and expedited review to CLN-081, a novel drug that is promising for the treatment of EGFR exon 20-mutated non-small cell lung cancer.
From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.
From celebrity deaths to exciting new treatments, here is CURE®’s roundup of what made waves in the brain cancer space this year.
2021 was full of research advancements and FDA drug approvals that continue to improve cancer care for patients with a variety of malignancies.
Many individuals were affected by cancer in the year 2021, including those in the spotlight. Here’s a roundup of the most-read cancer-related news impacting celebrities this year.
Upon recognizing the 50th anniversary of the National Cancer Act of 1971, President Joe Biden set forth his proposal for the Advanced Research Projects Agency for Health.
CURE® takes a look back at its top-performing breast cancer articles of 2021.
Take a look back at some of the major milestones in kidney cancer that were achieved in 2021.
A certified oncology nurse and board-certified adult nurse practitioner explained how the recent FDA approval of Darzalex Faspro, Kyprolis and dexamethasone may allow patients with relapsed/refractory multiple myeloma to switch treatments after discovering their current treatment is no longer working.
Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.
CURE® took a look back at our most-read lung cancer stories from this year.
Although the recent FDA approval of Keytruda was exciting for high-risk, nonmetastatic renal cell carcinoma, an expert from The University of MD Anderson Cancer Center notes more work is needed, particularly when it comes to individualizing treatment.
